AZD7545 是一种有效,竞争性和选择性的PDHK2抑制剂,对PDHK1和PDHK2的IC50分别为 36.8 nM 和 6.4 nM。
生物活性 | AZD7545 is a potent, competitive, selectivePDHK2(pyruvate dehydrogenase kinase 2) inhibitor withIC50s of 36.8 nM, 6.4 nM forPDHK1andPDHK2, respectively[1]. |
IC50& Target | IC50: 6.4 nM (PDHK2), 36.8 nM (PDHK1)[1] |
体外研究 (In Vitro) | AZD7545 (10 μM; 90 hours for BRAFV600Ehuman melanoma cells and 120 hours for NRASmuthuman melanoma cells) specifically suppresses growth of cells harboring BRAF and NRAS mutations as well as in inhibitor-resistant human melanoma[2].
Cell Proliferation Assay[2] Cell Line: | Human melanoma cells lines of BRAFV600E(A375, IGR37) and NRASmut(SKMel30, IPC298, MelJuso) | Concentration: | 10 μM | Incubation Time: | 90 hours (BRAFV600Ehuman melanoma cells) and 120 hours (NRASmuthuman melanoma cells) | Result: | Mediated growth suppression of BRAFV600Emutant and NRASmuthuman melanoma cells. |
|
体内研究 (In Vivo) | A single dose of AZD7545 (Oral administration; 10 mg/kg once a day (08:00 h) or Twice a day (08:00 and 18:00 h); for 7 days) to Wistar rats increases the proportion of liver PDH in its active, dephosphorylated form in a dose-related manner. A single dose of 10 mg/kg also significantly elevates muscle PDH activity in obese Zucker (fa/fa) rats[3].
Animal Model: | Obese male (fa/fa) Zucker rats[3] | Dosage: | 10 mg/kg | Administration: | Oral administration; once a day (08:00 h) or Twice a day ( 08:00 and 18:00 h); for 7 days | Result: | Improved the control of blood glucose levels. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : ≥ 46 mg/mL(96.06 mM) *"≥" means soluble, but saturation unknown. 配制储备液 1 mM | 2.0882 mL | 10.4412 mL | 20.8825 mL | 5 mM | 0.4176 mL | 2.0882 mL | 4.1765 mL | 10 mM | 0.2088 mL | 1.0441 mL | 2.0882 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (5.22 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (5.22 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (5.22 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (5.22 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (5.22 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (5.22 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|